The Efficacy, Mechanism of Action for the RSV Vaccines
In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).
The FDA approval of the Moderna RSV vaccine, mRNA 1345 (mRESVIA), was based from the results of the phase 3 ConquerRSV trial, which demonstrated an 83.7% efficacy against infection.
As there are now 3 FDA-approved RSV vaccines, Contagion has developed a new short series titled, Special Report: Clinical Insights on Moderna's RSV Vaccine. We have asked RSV vaccine investigators to provide more insights about these immunizations. Ann Falsey, MD, professor of Medicine at the University Of Rochester School Of Medicine, and her colleague, Edward Walsh, MD, professor of Medicine at the University Of Rochester School Of Medicine lead a peer-to-peer discussion on the impact these vaccines may have in preventing this respiratory illness.
In this second episode, Falsey and Walsh discuss the efficacy and mechanism of action of the various RSV vaccines.
